All In Biotech

Drug Trial Radar · NCT05125016

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Nov 30, 2021

Primary completion

Mar 28, 2030

Study completion Mar 28, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (how the body reacts to the drug) and effectiveness (how well the drug works to shrink tumors) of REGN4336 when given in combination with REGN5678. The study has 2 parts. The purpose of Part 1 is to determine a safe dose(s) of REGN4336 to be given alone or in combination with REGN5678. Part 1 is known as the "dose escalation" phase. The purpose of Part 2, (known as the "dose expansion" phase), is to use the doses of REGN4336 and REGN5678 selected in Part 1 to further test how well the combination treatment with REGN4336 and REGN5678 works to shrink tumors. The study is looking at several other research questions, including: * What side effects may happen from taking REGN4336 alone or in combination with REGN5678 * How well does REGN4336 in combination with REGN5678 reduce tumor size * How much REGN4336 is in the blood at different times when it is given alone or in combination with REGN5678 * Does the body make antibodies against the study drugs (REGN4336 or REGN5678)

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • REGN4336Drug

    Administered per the protocol

  • REGN5678Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: up to 21 days
  2. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
  3. Incidence and severity of Serious Adverse Events (SAEs)Time frame: Up to 5 years
  4. Incidence and severity of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 years
  5. REGN4336 monotherapy concentrations in serumTime frame: Up to 5 years
  6. REGN4336 concentrations in serum in combination with REGN5678Time frame: Up to 5 years
  7. Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)Time frame: Up to 5 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University Medical Center - Blake Wilbur Drive

    Palo Alto, California · Recruiting

  • Yale University Hospital

    New Haven, Connecticut · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • The Ohio State University James Cancer Hospital

    Columbus, Ohio · Recruiting

  • Penn Medicine University of Pennsylvania Health System

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Withdrawn

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.